Navigation Links
CHERISH trial demonstrates efficacy of tocilizumab in juvenile idiopathic arthritis
Date:6/12/2013

Madrid, Spain, 12 June 2013: A new study presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism shows that tocilizumab is efficacious and leads to a sustained clinically meaningful improvement in children with polyarticular Juvenile Idiopathic Arthritis (pcJIA).

Tocilizumab is a humanized recombinant antibody, which blocks the receptors where interleukin-6 (IL-6) attaches to the surface of cells. When IL-6 is unable to attach to these cells, they are prevented from driving inflammation. Elevated serum and joint fluid IL-6 levels have been shown to be associated with disease activity in patients with pcJIA.1

"JIA is a chronic arthritis occurring in 1 in every 1,000 children. With no known cause, it can lead to joint damage and permanent disability. These data show that tocilizumab rapidly improves signs and symptoms of pcJIA, with meaningful clinical responses maintained in a large proportion of patients at week 40," said lead author Dr. Fabrizio De Benedetti of the IRCCS Ospedale Pediatrico Bambino Gesu, Rome.

Speaking on behalf of the Paediatric Rheumatology International Trials Organisation (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG), who had overseen this study, Dr. De Benedetti concluded that "these data suggest that tocilizumab is going to be a novel biologic part of the therapeutic armamentarium for pcJIA."

CHERISH is a two-year, 3-part trial being conducted at 58 centres across 15 countries. Patients aged 2-17 years were included in the study if they had active pcJIA for at least 6 months and had failed to respond to methotrexate (a cornerstone of therapy worldwide for this condition).

Part 1 of the study was a 16-week open-label phase in which 188 patients received tocilizumab every four weeks. The 166 patients who achieved at least a 30% improvement in symptoms and signs of pcJIA (an JIA ACR30* response) went on to part 2, which was a 24-week
'/>"/>

Contact: EULAR Press Office
eularpressoffice@cohnwolfe.com
44-020-733-15364
European League Against Rheumatism
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Brain Tumor Vaccine Shows Promise in Early Trial
2. URMC clinical trial tests new regimen for hypertension
3. Analysis Finds Clinical Trials Often Small, of Poor Quality
4. US spends far more for health care than 12 industrialized nations, but quality varies
5. New Weight-Loss Drug Shows Promise in Trial
6. Palpitations are predictive of future atrial fibrillation
7. Trial Set to See if Drug Can Prevent Alzheimers
8. Experts call for clinical trials to test non-skeletal benefits of vitamin D
9. Breast cancer clinical trial tests combo of heat shock protein inhibitor and hormonal therapy
10. Canada should significantly increase its funding of randomized clinical trials
11. Alzheimers vaccine trial a success
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ... 2015 , ... BESLER Consulting today announced the firm has ... MarketingProfs Bright Bulb B2B Awards celebrate the best marketing, communications, and creative work ... their Readmissions Analytics product was selected as one of four finalists in the ...
(Date:8/3/2015)... ... August 03, 2015 , ... Novation, the nation’s largest ... pharmacogenetic lab testing and precision medicine solutions that can help pharmacists and other ... more than 8.6 million adverse drug events are reported in the U.S. ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... fitness site and the largest online retailer of nutritional supplements, has officially ... is up for 11 awards in the following categories:, ...
(Date:8/3/2015)... ... August 03, 2015 , ... Novatus, ... contract lifecycle management solution, as well as announced the date of its next ... and ease of contract management tasks as well as enhancements to the customer ...
(Date:8/3/2015)... ... August 03, 2015 , ... AxoGen, Inc. (NASDAQ: AXGN), a leader ... present at the Wedbush Healthcare Conference on Wednesday, August 12, 2015 at 9:45am (ET) ... archived replay of the Company’s presentation may be accessed via the investor relations section ...
Breaking Medicine News(10 mins):Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 2Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 3Health News:Novatus Unveils Milestone Software Release 2Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2
... Care and U.S. Soccer Federation team up to give ... a performance edge with better vision, JACKSONVILLE, Fla., March ... of ACUVUE(R) Brand Contact Lenses,today announced it is an official ... for the sport of soccer in the United,States., Under ...
... ANSYS, Inc.,(Nasdaq: ANSS ), a global innovator ... development processes, today announced it is a,sponsor of ... Carnegie Museum of,Natural History in Pittsburgh. This is ... scientifically accurate, immersive environments that are,composed of original ...
... Inc. (NYSE: HB ) (the "Company") announced today ... offer to purchase,any and all of its outstanding 4.50 ... $250 million in aggregate principal amount was,outstanding as of ... to an Offer to Purchase dated February 29, 2008 ...
... COM, VANCOUVER, March 17 /PRNewswire-FirstCall/ - ... positive interim clinical results,from its 90-day Phase ... analysis,demonstrated statistically significant efficacy for the patient ... compared to placebo. The,safety data from the ...
... Researchers will unveil a,new brain fitness training ... numerous,published studies to help people maintain health-related ... daily living tasks essential to,independence. The research ... neuroscience company, will introduce the new program, ...
... An investigational antiviral drug currently undergoing human trials ... potential to reduce muscle cell damage in Duchenne and ... led by Cincinnati Childrens Hospital Medical Center reported their ... a letter posted online March 16 by the journal ...
Cached Medicine News:Health News:U.S. Soccer Team Putting Vision in Focus for the Beijing 2008 Olympic Games 2Health News:U.S. Soccer Team Putting Vision in Focus for the Beijing 2008 Olympic Games 3Health News:ANSYS Sponsors Dinosaurs Exhibit at Carnegie Museum of Natural History 2Health News:ANSYS Sponsors Dinosaurs Exhibit at Carnegie Museum of Natural History 3Health News:Hillenbrand Industries, Inc. Announces Early Tender Results of its Pending 'Any and All' Cash Tender Offer for its 4.50 Percent Senior Notes Due 2009 2Health News:Hillenbrand Industries, Inc. Announces Early Tender Results of its Pending 'Any and All' Cash Tender Offer for its 4.50 Percent Senior Notes Due 2009 3Health News:Hillenbrand Industries, Inc. Announces Early Tender Results of its Pending 'Any and All' Cash Tender Offer for its 4.50 Percent Senior Notes Due 2009 4Health News:Hillenbrand Industries, Inc. Announces Early Tender Results of its Pending 'Any and All' Cash Tender Offer for its 4.50 Percent Senior Notes Due 2009 5Health News:Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor 2Health News:Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor 3Health News:Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor 4Health News:Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor 5Health News:Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor 6Health News:New Brain Fitness Training Promotes Health and Independence of Long Term Care Insurance Policyholders 2Health News:New Brain Fitness Training Promotes Health and Independence of Long Term Care Insurance Policyholders 3Health News:Investigational drug tested for preventing muscle fiber death in muscular dystrophy 2Health News:Investigational drug tested for preventing muscle fiber death in muscular dystrophy 3
(Date:8/3/2015)... PAUL, Minn. , Aug. 3, 2015  EnteroMedics ... using neuroblocking therapy to treat obesity, metabolic diseases and ... McDougal has been appointed to the Board of ... as a Class II Director until the 2018 annual ... Ms. McDougal has served in an executive ...
(Date:8/2/2015)... 2015 Mandatory takeover offer ... ("Dechra" or the "Company") is pleased to announce the ... Mr. Marijan Han žeković to acquire his 63.3% ... ("Genera"), a Croatian listed pharmaceutical business.   ... equivalent to €51.4 million for the entire share capital ...
(Date:7/31/2015)... -- Seeger Weiss LLP is reporting that on July 13, 2015, ... C.R. Bard, the manufacturer of Inferior vena cava (IVC) ... the agency found at two of Bard,s facilities. Bard was ... them during Inspectional Observations that occurred on November 18, 2014, ... , location and on October 6, 2014, through November ...
Breaking Medicine Technology:EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 2EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 3Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 2Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 3Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 4Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 5Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 3
DePuy's Shoe Boots are sealed thermoplastic boots that help provide splash protection from microorganisms, particulate matter and body fluids....
... System rede phines sharpness and efficiency ... for penetrating keratoplasty. Advanced trephine blade ... to achieve the critical fit needed for ... fully customized system enables surgeons to select ...
The MP-1 Microperimeter delivers an accurate, fully automatic assessment of the macular function. This is achieved by effectively integrating in a single instrument the objectivity of fundus imaging ...
PacePath is a comprehensive anatomic pathology software system that is the culmination of more than five years of development and testing by leading industry experts....
Medicine Products: